RASSF1 and cervical cancer: In conclusion, the present studies clearly showed that MEG3, MYOD1, CALCA, hTERT, and RASSF1A methylation in plasma can serve as diagnostic and prognostic biomarkers for cervical cancer patients, providing useful information for clinical management.